EML4-ALK fusion gene
US7605131B2 · kind B2 · utility
19Cited by
0References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 10, 2008 |
| Grant date | Oct 20, 2009 |
| Priority date | — |
| Expiry date | Apr 10, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, and a therapeutic agent for cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.